H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Revance Therapeutics (NASDAQ:RVNC) on Tuesday, setting a price target of $35, which is approximately 27.60% above the present share price of $27.43.
Tsao expects Revance Therapeutics to post earnings per share (EPS) of -$1.24 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Revance Therapeutics, with an average price target of $35.5.
The analysts price targets range from a high of $45 to a low of $26.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $11.13 million and a net profit of -$77.97 million. The company's market cap is $1.96 billion.
According to TipRanks.com, H.C. Wainwright analyst Douglas Tsao is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.4% and a 48.97% success rate.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.